The neurobiology of depression: Inroads to treatment and new drug discovery

Journal of Clinical Psychiatry

Volumn 66, Issue SUPPL. 7, 2005, Pages 5-13

  Nemeroff, Charles B ^a   Vale, Wylie W ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; ANTALARMIN; ANTIDEPRESSANT AGENT; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; HYDROCORTISONE; NBI 34041; NEFAZODONE; PAROXETINE; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADAPTATION; ANXIETY DISORDER; AUTOSOMAL DOMINANT INHERITANCE; CHROMOSOME MAP; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DNA SEQUENCE; DOSE RESPONSE; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOME ANALYSIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIVER TOXICITY; MENTAL DISEASE; MOLECULAR CLONING; MOOD DISORDER; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PSYCHOTHERAPY; RISK FACTOR; SEXUAL ABUSE; SIGNAL TRANSDUCTION; STRESS; TREATMENT OUTCOME;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANIMALS; ANTIDEPRESSIVE AGENTS; CHILD; CHILD ABUSE; CORTICOTROPIN-RELEASING HORMONE; DEPRESSIVE DISORDER; DRUG DESIGN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROCORTISONE; LIFE CHANGE EVENTS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SOCIAL ENVIRONMENT; STRESS, PSYCHOLOGICAL;

EID: 25144441630     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (83)

1. Uhl GR, Grow RW. The burden of complex genetics in brain disorders. Arch Gen Psychiatry 2004;61:223-229
2. Reinherz HZ, Paradis AD, Giaconia RM, et al. Childhood and adolescent predictors of major depression in the transition to adulthood. Am J Psychiatry 2003;160:2141-2147
3. Charney DS, Manji HK. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE 2004;225:re5
4. Cowan WM, Kopnisky KL, Hyman SE. The human genome project and its impact on psychiatry. Annu Rev Neurosci 2002;25:1-50
5. Li T, Ball D, Zhao J, et al. Family-based linkage disequilibrium mapping using SNP marker haplotypes: application to a potential locus for schizophrenia at chromosome 22q11. Mol Psychiatry 2000;5:77-84
6. Peters EJ, Slager SL, McGrath PJ, et al. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004;9:879-889
7. Wu CC, Reilly JF, Young WG, et al. High-throughput morphometric analysis of individual neurons. Cereb Cortex 2004;14:543-554
8. Collier DA, Stober G, Li T, et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role insusceptibility to affective disorders. Mol Psychiatry 1996;1:453-460
9. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531
10. van Dyck CH, Malison RT, Staley JK, et al. Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype. Am J Psychiatry 2004;161:525-531
11. Sander T, Harms H, Dufeu P, et al. Serotonin transporter gene variants in alcohol-dependent subjects with dissocial personality disorder. Biol Psychiatry 1998;43:908-912
12. Greenberg BD, Li Q, Lucas FR, et al. Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population sample. Am J Med Genet 2000;96:202-216
13. Jacob CP, Strobel A, Hohenberger K, et al. Association between allelic variation of serotonin transporter function and neuroticism in anxious cluster C personality disorders. Am J Psychiatry 2004;161:569-572
14. Mossner R, Henneberg A, Schmitt A, et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry 2001;6:350-352
15. Meyer J, Saam W, Mossner R, et al. Evolutionary conserved microsatellites in the promoter region of the 5-hydroxytryptamine receptor 2C gene (HTR2C) are not associated with bipolar disorder in females. J Neural Transm 2002;109:939-946
16. Sand P, Lesch KP, Catalano M, et al. Polymorphic MAO-A and 5-HT-transporter genes: analysis of interactions in panic disorder. World J Biol Psychiatry 2000;1:147-150
17. Kaufman J, Yang BZ, Douglas-Palumberi H, et al. Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci U S A 2004;101:17316-17321
18. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-389
19. Bale TL, Contarino A, Smith GW, et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000;24:410-414
20. Nemeroff CB. The neurobiology of depression. Sci Am 1998;278:42-49
21. Vale W, Spiess J, Rivier C, et al. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and beta-endorphin. Science 1981;213:1394-1397
22. Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 2004;44:525-557
23. Chen R, Lewis KA, Perrin MH, et al. Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U S A 1993;90:8967-8971
24. Hauger RL, Grigoriadis DE, Dallman MF, et al. International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev 2003;55:21-26
25. Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995;378:287-292
26. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001;7:605-611
27. Lewis K, Li C, Perrin MH, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A 2001;98: 7570-7575
28. Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A 2001;98: 2843-2848
29. Valdez GR, Zorrilla EP, Rivier J, et al. Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res 2003;980:206-212
30. Skelton KH, Nemeroff CB, Owens MJ. Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expression. J Neurosci 2004;24:9303-9312
31. Smith GW, Aubry JM, Dellu F, et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998;20:1093-1102
32. Timpl P, Spanagel R, Sillaber I, et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998;19:162-166
33. Coste SC, Kesterson RA, Heldwein KA, et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin- releasing hormone receptor-2. Nat Genet 2000;24:403-409
34. Bale TL, Picetti R, Contarino A, et al. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J Neurosci 2002;22:193-199
35. Banki CM, Bissette G, Arato M, et al. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 1987;144:873-877
36. Merali Z, Du L, Hrdina P, et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 2004;24: 1478-1485
37. Nemeroff CB, Widerlov E, Bissette G, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342-1344
38. Raadsheer FC, Hoogendijk WJ, Stam FC, et al. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994; 60:436-444
39. Kendler KS, Neale MC, Kessler RC, et al. Childhood parental loss and adult psychopathology in women: a twin study perspective. Arch Gen Psychiatry 1992;49:109-116
40. Chapman DP, Whitfield CL, Felitti VJ, et al. Adverse childhood experiences and the risk of depressive disorders in adulthood. J Affect Disord 2004;82:217-225
41. Dube SR, Anda RF, Felitti VJ, et al. Childhood abuse, household dysfunction, and the risk of attempted suicide throughout the life span: findings from the Adverse Childhood Experiences Study. JAMA 2001;286: 3089-3096
42. McCauley J, Kern DE, Kolodner K, et al. Clinical characteristics of women with a history of childhood abuse: unhealed wounds. JAMA 1997;277: 1362-1368
43. Safren SA, Gershuny BS, Marzol P, et al. History of childhood abuse in panic disorder, social phobia, and generalized anxiety disorder. J Nerv Ment Dis 2002;190:453-456
44. Gutman DA, Nemeroff CB. Persistent central nervous system effects of an adverse early environment: clinical and preclinical studies. Physiol Behav 2003;79:471-178
45. Heim C, Newport DJ, Bonsall R, et al. Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatry 2001;158:575-581
46. Heim C, Newport DJ, Heit S, et al. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 2000;284:592-597
47. Finamore TL, Port RL. Developmental stress disrupts habituation but spares prepulse inhibition in young rats. Physiol Behav 2000;69:527-530
48. Plotsky PM, Thrivikraman KV, Nemeroff CB, et al. Long-term consequences of neonatal rearing on central corticotropin-releasing factor systems in adult male rat offspring. Neuropsychopharmacology. In press
49. Ladd CO, Huot RL, Thrivikraman KV, et al. Long-term behavioral and neuroendocrine adaptations to adverse early experience. Prog Brain Res 2000;122:81-103
50. Plotsky PM, Meaney MJ. Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF con-tent and stress-induced release in adult rats. Brain Res Mol Brain Res 1993;18:195-200
51. Neumaier JF, Edwards E, Plotsky PM. 5-HT(1B) mRNA regulation in two animal models of altered stress reactivity. Biol Psychiatry 2002;51: 902-908
52. Caldji C, Francis D, Sharma S, et al. The effects of early rearing environment on the development of GABA-A and central benzodiazepine receptor levels and novelty-induced fearfulness in the rat. Neuropsychopharmacology 2000;22:219-229
53. Meaney MJ, Brake W, Gratton A. Environmental regulation of the development of mesolimbic dopamine systems: a neurobiological mechanism for vulnerability to drug abuse? Psychoneuroendocrinology 2002;27:127-138
54. Huot RL, Plotsky PM, Lenox RH, et al. Neonatal maternal separation reduces hippocampal mossy fiber density in adult Long Evans rats. Brain Res 2002;950:52-63
55. Mirescu C, Peters JD, Gould E. Early life experience alters response of adult neurogenesis to stress. Nat Neurosci 2004;7:841-846
56. Huot RL, Thrivikraman KV, Meaney MJ, et al. Development of adult ethanol preference and anxiety as a consequence of neonatal maternal separation in Long Evans rats and reversal with antidepressant treatment. Psychopharmacology (Berl) 2001;158:366-373
57. Matthews K, Robbins TW, Everitt BJ, et al. Repeated neonatal maternal separation alters intravenous cocaine self-administration in adult rats. Psychopharmacology (Berl) 1999;141:123-134
58. Caldji C, Tannenbaum B, Sharma S, et al. Maternal care during infancy regulates the development of neural systems mediating the expression of fearfulness in the rat. Proc Natl Acad Sci U S A 1998;95:5335-5340
59. Newport DJ, Stowe ZN, Nemeroff CB. Parental depression: animal models of an adverse life event. Am J Psychiatry 2002;159:1265-1283
60. Huot RL, Gonzalez ME, Ladd CO, et al. Foster litters prevent hypothalamic-pituitary-adrenal axis sensitization mediated by neonatal maternal separation. Psychoneuroendocrinology 2004;29:279-289
61. Francis DD, Diorio J, Plotsky PM, et al. Environmental enrichment reverses the effects of maternal separation on stress reactivity. J Neurosci 2002;22:7840-7843
62. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-1847
63. Mullen PE, Martin JL, Anderson JC, et al. The long-term impact of the physical, emotional, and sexual abuse of children: a community study. Child Abuse Negl 1996;20:7-21
64. Young EA, Abelson JL, Curtis GC, et al. Childhood adversity and vulnerability to mood and anxiety disorders. Depress Anxiety 1997;5:66-72
65. Newport DJ, Heim C, Owens MJ, et al. Cerebrospinal fluid corticotropin-releasing factor (CRF) and vasopressin concentrations predict pituitary response in the CRF stimulation test: a multiple regression analysis. Neuropsychopharmacology 2003;28:569-576
66. Carpenter LL, Tyrka AR, McDougle CJ, et al. Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects. Neuropsychopharmacology 2004;29:777-784
67. Vythilingam M, Heim C, Newport J, et al. Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry 2002;159:2072-2080
68. Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 1998;9:2023-2028
69. Bremner JD, Randall P, Vermetten E, et al. Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse: a preliminary report. Biol Psychiatry 1997;41:23-32
70. Stein MB, Koverola C, Hanna C, et al. Hippocampal volume in women victimized by childhood sexual abuse. Psychol Med 1997;27:951-959
71. Duman RS, Charney DS. Cell atrophy in major depression [editorial]. Biol Psychiatry 1999;45:1083-1084
72. Brunson KL, Eghbal-Ahmadi M, Bender R, et al. Long-term, progressive hippocampal cell loss and dysfunction induced by early-life administration of corticotropin-releasing hormone reproduce the effects of early-life stress. Proc Natl Acad Sci U S A 2001;98:8856-8861
73. Kilts CD, Ely TD, Newport JD, et al. Childhood trauma is associated with altered neural processing related to emotion perception and memory [abstract]. Biol Psychiatry 2005;57:62S
74. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-1470
75. Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A 2003;100: 14293-14296
76. Gorman JM. New molecular targets for antianxiety interventions. J Clin Psychiatry 2003;64(suppl 3):28-35
77. Zobel AW, Nickel T, Künzel HE, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000;34:171-181
78. Deak T, Nguyen KT, Ehrlich AL, et al. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 1999;140:79-86
79. Seymour PA, Schmidt AW, Schulz DW. The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review. CNS Drug Rev 2003;9:57-96
80. Willenberg HS, Bornstein SR, Hiroi N, et al. Effects of a novel corticotropin-releasing-hormone receptor type I antagonist on human adrenal function. Mol Psychiatry 2000;5:137-141
81. Schulz DW, Mansbach RS, Sprouse J, et al. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci U S A 1996;93:10477-10482
82. Shaham Y, Erb S, Leung S, et al. CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor 1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology (Berl) 1998;137:184-190
83. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241